Defymed's exclusive technology and know-how positions its medical devices as a platform to meet several therapeutic applications, including type 1 diabetes, hemophilia, and cancer management. The company's solutions aim for a precise administration of drugs in a physiologic site to improve disease management and patients' quality of life. Defymed's two first-in-class technologies, MailPan® and ExOlin®, were developed to limit adverse events related to current standard of care based on site-specific delivery of therapeutics. The company is certified ISO13485:2016 and relies on a strong worldwide network of experts from the cell therapy and drug delivery fields.